CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

You are here

Products

Products

back to search results

TLE1 [TLE1/2062]

Product information References Bioinformatics Documents
Product group: Primary
Monoclonal/ Polyclonal: Monoclonal
Clone: TLE1/2062
Host: Mouse
Isotype: IgG2a
Application: Immunohistochemistry (IHC), Western Blot (WB)
Application notes: Prediluted
Conjugation Type: Unconjugated
Lightchain type: Kappa
Reactivity: Human
General notes: Localization: nucleus.
Buffer: citrate pH6.0 or EDTA pH8.0
UNSPSC code: 12352203

Transducin-like enhancer of split 1 (TLE1) gene is a member of the TLE gene family and involved in control of hematopoiesis, neuronal, and terminal epithelial differentiation. By immunohistochemistry in formalin-fixed, paraffin-embedded tissues, TLE1 expression (nuclear staining) has been found in 35 of 35 molecularly confirmed synovial sarcoma cases, and was rare to absent in the 73 other soft tissue tumors examined (positive staining was found only in 1 of 43 malignant peripheral nerve sheath tumors and 1 pleomorphic sarcoma). Anti-TLE1 was more sensitive and specific for synovial sarcoma than other currently available immunohistochemical markers including BCL2, epithelial membrane antigen and cytokeratins, and had a positive predictive value of 92% and a negative predictive value of 100% in this clinical setting. TLE1 overexpression by immunohistochemistry is a highly sensitive and specific biomarker for the diagnosis of synovial sarcoma in the group of otherwise unclassifiable high

TLE1 [TLE1/2062]

Transducin-like enhancer of split 1 (TLE1) gene is a member of the TLE gene family and involved in control of hematopoiesis, neuronal, and terminal epithelial differentiation. By immunohistochemistry in formalin-fixed, paraffin-embedded tissues, TLE1 expression (nuclear staining) has been found in 35 of 35 molecularly confirmed synovial sarcoma cases, and was rare to absent in the 73 other soft tissue tumors examined (positive staining was found only in 1 of 43 malignant peripheral nerve sheath tumors and 1 pleomorphic sarcoma). Anti-TLE1 was more sensitive and specific for synovial sarcoma than other currently available immunohistochemical markers including BCL2, epithelial membrane antigen and cytokeratins, and had a positive predictive value of 92% and a negative predictive value of 100% in this clinical setting. TLE1 overexpression by immunohistochemistry is a highly sensitive and specific biomarker for the diagnosis of synovial sarcoma in the group of otherwise unclassifiable high-grade sarcomas.